Eyeing emerging markets, Abbott nabs Zydus Cadila deal

Abbott Laboratories (NYSE: ABT) says it has entered into a licensing agreement to commercialize products of India's Zydus Cadila in 15 emerging markets in a bid to accelerate Abbott's growth in those areas; the company also set up a business unit to concentrate on the developing world. Release | Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.